We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > sBLA

News List

FDA agrees to review Merck and Pfizer’s sBLA for Bavencio and Inlyta pharmaceutical-technology
February 13, 2019
The US Food and Drug Administration (FDA) has accepted a supplemental biologics license application (sBLA) submitted by Merck subsidiary EMD Serono and Pfizer for a Bavencio (avelumab) and Inlyta (axitinib) combination to .....
FDA Approves Eylea Injection sBLA americanpharmaceuticalreview
August 20, 2018
Regeneron Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Eylea (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD).
FDA Accepts for Filing Supplemental Biologics License Application (sBLA) for Xeomin® (incobotulinumt biospace
March 15, 2018
Merz North America announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (sBLA)
FDA Accepts sBLA for Prolia in Glucocorticoid-Induced Osteoporosis americanpharmaceuticacreview
October 11, 2017
Glucocorticoid medications, which are used to treat many inflammatory conditions, can cause significant side effects, including bone loss.